United Therapeutics Corporation
UTHR
$322.94
$15.705.11%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.74% | 4.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.74% | 4.76% | |||
| Cost of Revenue | -8.66% | 6.81% | |||
| Gross Profit | -0.87% | 4.50% | |||
| SG&A Expenses | 6.62% | -13.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.77% | -13.75% | |||
| Operating Income | -11.34% | 27.60% | |||
| Income Before Tax | 2.03% | 9.37% | |||
| Income Tax Expenses | 19.75% | 2.98% | |||
| Earnings from Continuing Operations | -2.52% | 11.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.52% | 11.15% | |||
| EBIT | -11.34% | 27.60% | |||
| EBITDA | -10.70% | 26.20% | |||
| EPS Basic | -2.74% | 10.65% | |||
| Normalized Basic EPS | -10.85% | 26.11% | |||
| EPS Diluted | -3.22% | 9.23% | |||
| Normalized Diluted EPS | -11.20% | 24.32% | |||
| Average Basic Shares Outstanding | 0.22% | 0.45% | |||
| Average Diluted Shares Outstanding | 0.62% | 1.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
